Cumulative Index

FEBRUARY–AUGUST

Page numbers of symposium and clinic titles are given in **boldface** type.

ABNORMALITIES. See also under organs and regions.
chromosomal. See *Chromosomes, abnormalities.*
congenital, of heart and great vessels, *Feb.*, **55–105**
or developmental, pyelonephritis due to, *Aug.*, 736, 737
relation to gynecologic surgery, *Feb.*, 46–50
Ebstein's anomaly, *Feb.*, 132; *May*, 279
treatment, *May*, 307
Taussig-Bing deformity, *Feb.*, 133
Acetazolamide (Diamox) in cardiac arrhythmias, *May*, 358
Acetylcholine bromide in supraventricular tachycardia, *May*, 328, 329
Acetyldigitoxin (Acylanid), *May*, 238
dosage, *May*, 241
Acetylsalicylic acid (aspirin)
in rheumatic fever, *May*, 220
poisoning, fluid therapy in, *Feb.*, 11
Achylia, pancreatic, in cystic fibrosis, *Feb.*, 143
Acid-base disorders, renal. See *Kidneys, acid-base disorders.*
Acidification of urine, *Aug.*, 612
Acidosis. See also *Alkalosis.*
chronic, relation to growth retardation, *Aug.*, 564–7
diabetic, fluid therapy in, *Feb.*, 10
in diarrhea, *Feb.*, 6–7
renal, *Aug.*, 614–22
sodium bicarbonate in, *Feb.*, 5
Actinomycin D in nephroblastoma, *Feb.*, 40
Activity. See also *Exercise.*
during convalescence from glomerulonephritis, *Aug.*, 645–6
in cystic fibrosis of pancreas, *Feb.*, 145
in rheumatic fever, *May*, 223
Acylanid. See *Acetyldigitoxin.*
Adams-Stokes attacks, death in myocarditis due to, *May*, 418
Adrenals. See also *Cushing's syndrome.*
cortex, insufficiency, fluid therapy in, *Feb.*, 11
hyperplasia, congenital, *Feb.*, 46–7
hypertension due to, *May*, 447
influence of steroid therapy on, *Feb.*, 20
tumors, aldosterone-secreting hypertension due to, *May*, 447
Adrenocortical hormones in shock, *May*, 477–9
Adrenocortical insufficiency, fluid therapy in, *Feb.*, 11
Adrenocorticosteroids in myocarditis, *May*, 413
Advances, clinical
in pediatric allergy, *Feb.*, **17–31**
in pediatric surgery, *Feb.*, **33–44**
symposium on, *Feb.*, **1–200**
Aerosol treatments in cystic fibrosis of pancreas, *Feb.*, 144
Aganglionic megacolon, *Feb.*, 38
Age, relation to blood pressure, *May*, 432, 433
Agenesis, ovarian, *Feb.*, 48
Airway. See *Respiratory tract.*
Albumin for shock in diarrhea, *Feb.*, 6
Albuminuria, relation to growth retardation, *Aug.*, 569–70
Aldactone. See *Spironolactone.*
Aldosterone-secreting tumors of adrenals, hypertension due to, *May*, 447
Aldosteronism, primary, hypertension due to, surgical treatment, *May*, 459
Alkalosis. See also *Acidosis.*
renal, *Aug.*, 622–6
Allergy. See also *Asthma; Eczema.*
advances in last 10 years, *Feb.*, **17–31**
bacterial, asthma due to, *Feb.*, 22
steroid therapy, *Feb.*, 18–21
to cow's milk, *Feb.*, 22–7
Aminoaciduria, relation to growth retardation, *Aug.*, 569–70
Aminophylline in cardiac arrhythmias, *May*, 359

Ammonia excretion, *Aug.*, 613–14
Anemia
and erythropoiesis in renal disease, *Aug.*, 667–73
due to diarrhea, blood transfusion for, *Feb.*, 5
hemolytic, microangiopathic, *Aug.*, 588
thrombocytopenia and renal disease, *Aug.*, **577–91**
in renal disease, treatment, *Aug.*, 672, 673
Anesthesia. See also *Surgery.*
advances in, *Feb.*, 42
Aneurysm of aortic sinus, rupture into right atrium, *Feb.*, 62
Anomalies. See *Abnormalities;* and under organs and regions.
Anoxemia vs. heart failure, *May*, 255
Ansolysen. See *Pentolinium.*
Antibiotics. See also specific drugs.
in cystic fibrosis of pancreas, *Feb.*, 145
in pneumonia complicating acyanotic congenital heart disease, *May*, 311, 312
Antibodies
comparison with interferon, *Aug.*, 552
cross-reacting, in immunologic disease, *Aug.*, 710–711
local, *Aug.* 554–5
mucoantibody, *Aug.*, 554–5
streptococcal, in diagnosis of rheumatic fever, *May*, 214
systemic, *Aug.*, 552–4
Antigen-antibody-complex renal disease. See *Kidneys, disease, antigen-antibody-complex.*
Antihistaminics in pneumonia complicating acyanotic congenital heart disease, *May*, 311
Antimicrobial therapy in pyelonephritis, *Aug.*, 663–4
Antipyresis in shock, *May*, 474–5
Antirheumatic agent in rheumatic fever, *May*, 218–19
Antiviral mechanisms
nonspecific, *Aug.*, 549–52
specific, *Aug.*, 552–5
Anuria, fluid therapy in, *Feb.*, 12
Anus, imperforate, surgical advances in, *Feb.*, 35–6
Aorta
coarctation, *Feb.*, 111–12, 135
hypertension due to, *May*, 445, 446
surgical treatment, *May*, 460
treatment, *May*, 308–309
left ventricular hypertrophy with shunts arising from, *Feb.*, 117–19
Aortic arch, interruption proximal to patent ductus arteriosus and ventricular septal defect, *Feb.*, 82
Aortic-pulmonary window, *May*, 305–306
Aortic runoffs, hypertension due to, *May*, 446
Aortic sinus, aneurysm, rupture of
into right atrium, *Feb.*, 62
into right ventricle, *Feb.*, 64
Aortic valve
atresia, *Feb.*, 129
regurgitation complicating ventricular septal defect, *Feb.*, 120
stenosis, *Feb.*, 112, 135
treatment, *May*, 308
Aorticopulmonary septal defect, *Feb.*, 74
vs. classic patent ductus arteriosus, *Feb.*, 66
with occlusive pulmonary vascular disease, *Feb.*, 82
Aorticopulmonary window, *Feb.*, 118
Apresoline. See *Hydralazine hydrochloride.*
Aramine. See *Metaramine.*
Arfonad. See *Trimethaphan.*
Arrest, cardiac, *May*, 353–6
Arrhythmias. See also *Heart, block; Heart, rate.*
bigeminy, *May*, 334
death in myocarditis due to, *May*, 422–3
due to digitalis, *May*, 237
postoperative, in cyanotic congenital heart disease, *May*, 288–9
rhythms arising in atria, *May*, 322–34
rhythms arising in ventricle, *May*, 334–41
rhythms originating from sinus node, *May*, 316–22
rhythms originating in atrioventricular node, *May*, 334
sinus, *May*, 319–20
treatment, *May*, **315–62**
Arteries. See also *Aneurysm; Aorta; Blood pressure; Blood vessels; Ductus arteriosus; Emboli; Thrombosis;* etc.
coronary, accessory, arising from pulmonary trunk, *Feb.*, 66
anomalous communication with coronary sinus or right atrium, *Feb.*, 62
communication with right ventricle, *Feb.*, 64
left, anomalous, *Feb.*, 113
anomalous origin from pulmonary trunk, *Feb.*, 66
great, transposition of, complete, *May*, 279–81
pulmonary, *Feb.*, 115
and left atrium, direct connection between, *Feb.*, 100
coarctation, *Feb.*, 115
normal, *Feb.*, 57
with cyanosis, *Feb.*, 89–101

Arteries (*Continued*)
pulmonary, normal, with cyanosis, with normal right ventricular and pulmonary arterial pressures, *Feb.*, 98–101
with right ventricular hypertension without pulmonary arterial hypertension, *Feb.*, 89–97
without cyanosis, *Feb.*, 77
prominent, with cyanosis, *Feb.*, 78–88
with normal right ventricular and pulmonary arterial pressures, *Feb.*, 79
with right ventricular and pulmonary arterial hypertension, *Feb.*, 80–88
without cyanosis, *Feb.*, 58–76
with normal right ventricular and pulmonary arterial pressures, *Feb.*, 59–67
with right ventricular and pulmonary arterial hypertension, *Feb.*, 68–75
with right ventricular hypertension without pulmonary arterial hypertension, *Feb.*, 76
renal, stenosis of, hypertension due to, *May*, 441 ff.
thrombosis, *Aug.*, 537–40
Arterioles, glomerular, thrombosis of, *Aug.*, 540–41
Arteriovenous fistula, pulmonary, *Feb.*, 100
Asphyxia, birth, *May*, 369–73
Aspiration pneumonia, meconium, with acute cor pulmonale, *May*, 397–8
Aspirin. See *Acetylsalicylic acid.*
Asthma. See also *Allergy.*
bacterial sensitization in, *Feb.*, 21–2
due to bacterial allergy, *Feb.*, 22
Ataractics in cardiac arrhythmias, *May*, 358
Atarax. See *Hydroxyzine hydrochloride.*
Atresia. See under organ or region affected.
Atrial extrasystoles, *May*, 323
Atrial fibrillation, *May*, 332–4
Atrial flutter, *May*, 331–2
Atrial septal defect, *Feb.*, 121–2, 135
associated with mitral valve cleft, *Feb.*, 60
at fossa ovalis, *Feb.*, 60
complicated, *Feb.*, 122–3
complicating ventricular septal defect, *Feb.*, 120
ostium secundum, *May*, 303–304
sinus venosus type, *Feb.*, 79
Atrial septal defect (*Continued*)
superior to fossa ovalis, *Feb.*, 79
treatment, *May*, 312–13
with occlusive pulmonary vascular disease, *Feb.*, 80
Atrial shunt, left-to-right, *May*, 303–304
Atrial tachycardia, paroxysmal, with block, *May*, 330–31
Atrioventricular block, *May*, 343–8
death in myocarditis due to, *May*, 416, 417, 418, 419
first-degree, *May*, 343–4
second-degree, *May*, 344–5
Atrioventricular canal, common, persistent, *Feb.*, 70
Atrioventricular dissociation, *May*, 342–3
death in myocarditis due to, *May*, 417
Atrioventricular valves, patent, and transposition of great vessels, with common ventricle, *Feb.*, 86
Atrioventricularis communis, *Feb.*, 122, 124
Atrium
common, *May*, 278–9
left, and pulmonary artery, direct connection between, *Feb.*, 100
connection of systemic vein with, *Feb.*, 100
rhythms arising in, *May*, 322–34
right, anomalous communication of coronary artery with, *Feb.*, 62
blood shunt into, *Feb.*, 60–63
communication with left ventricle, *Feb.*, 62
rupture of aneurysm of aortic sinus into, *Feb.*, 62
Azotemia. See *Uremia.*

BACTEREMIA
shock syndrome in, *May*, 468
with urinary infection, *Aug.*, 525
Bacteria. See also *Viruses.*
allergy to, asthma due to, *Feb.*, 22
endocarditis due to. See *Endocarditis, bacterial.*
sensitization in asthma, *Feb.*, 21–2
Bacteriologic findings in urinary tract infections, interpretation, *Aug.*, 525–8
Bacteriology
and immune response in urinary tract infections, *Aug.*, **517–31**
urinary tract, quantitative aspects, *Aug.*, 522–4
Bacteriuria, *Aug.*, 518
and bladder catheterization, *Aug.*, 747–8
perinatal death due to, *Aug.*, 749

Bacteriuria (*Continued*)
pregnancy and perinatal morbidity and mortality, *Aug.*, 748–9
relation to pyelonephritis, *Aug.*, 747
significance, *Aug.*, 747–50
tests for, *Aug.*, 744
vs. contamination of urine, *Aug.*, 743
Benemid. See *Probenecid.*
Bicarbonate reabsorption, *Aug.*, 612–13
Bigeminy, *May*, 334
Biliary tract. See also *Gallbladder; Liver.*
atresia, *Feb.*, 42
Birth. See also *Infants; Newborn.*
asphyxia, *May*, 369–73
circulation changes at, *May*, 364–8
Bisodium ethylene diamine tetraacetic acid (Sodium Versenate) in cardiac arrhythmias, *May*, 359
Bladder. See also *Urinary tract.*
catheterization, bacteriuria and, *Aug.*, 747–8
exstrophy, surgical advances in, *Feb.*, 40–41
Blastema, metanephric, *Aug.*, 759
Bleeding abnormalities in renal disease, *Aug.*, 673–4
Blood. See also *Anemia.*
circulation, changes at birth, *May*, 364–8
in fetus, *May*, 364–8
maintenance in shock, *May*, 470–73
cultures in bacterial endocarditis, *May*, 486
loss. See *Hemorrhage.*
plasmatic factors in renal disease, *Aug.*, 674
platelets, reduction, in renal disease, *Aug.*, 673
pressure, after operation, *May*, 461
determinations, *May*, 432–4; *Aug.*, 723, 724
effect of digitalis on, *May*, 234–5
high. See *Hypertension.*
medians, *May*, 431
relation to age, *May*, 432, 433
restoration in shock, *May*, 475–7
shunt, in congenital heart disease, direction of, *Feb.*, 109
lesions with, *Feb.*, 110–17
presence of, *Feb.*, 108–109
into pulmonary trunk, *Feb.*, 66
into right atrium, *Feb.*, 60–63
left-to-right, in congenital heart disease, lesions with, *Feb.*, 117–24
with right ventricular hypertrophy, *Feb.*, 121–3
right-to-left, at atrial level, with pulmonic stenosis and intact ventricular septum, *May*, 274–5
Blood (*Continued*)
shunt, right-to-left, in congenital heart disease, lesions with, *Feb.*, 124–30
transfusion, exchange, in erythroblastosis fetalis, *May*, 375
in anemia, *Feb.*, 5, 6
in anemia of renal disease, *Aug.*, 673
in shock, *Feb.*, 5, 6; *May*, 473–4
postoperative, in cyanotic congenital heart disease, *May*, 284–5
Blood vessels. See also *Aorta; Arteries; Veins*, etc.
disease, renal, *Aug.*, **533–47**
great, congenital anomalies, *Feb.*, 55–105
normal, and subpulmonary stenosis, with tricuspid atresia, *Feb.*, 98
with tricuspid atresia, *Feb.*, 86
origin from right ventricle with pulmonary stenosis, *Feb.*, 92
origin from right ventricle without pulmonary stenosis, *Feb.*, 74, 84
transposition, *Feb.*, 128, 132–3, 134
and mitral atresia, with common ventricle, *Feb.*, 86
and patent atrioventricular valves, with common ventricle, *Feb.*, 86
and subpulmonary stenosis, with tricuspid atresia, *Feb.*, 98
and tricuspid atresia, with common ventricle, *Feb.*, 86
complete, *May*, 279–81
corrected, *Feb.*, 72
and large ventricular septal defect, *Feb.*, 72
and ventricular septal defect with pulmonary vascular disease, *Feb.*, 80
complicating ventricular septal defect, *Feb.*, 120–21
ventricular septal and mitral insufficiency, *Feb.*, 72
with closed ductus arteriosus and intact ventricular septum, *Feb.*, 90
with patent ductus arteriosus and interatrial communication, *Feb.*, 88
with pulmonic stenosis, *Feb.*, 131–2
with subpulmonary stenosis and ventricular septal defect, *Feb.*, 90
with subpulmonary stenosis, intact ventricular septum and closed ductus arteriosus, *Feb.*, 90
with tricuspid atresia and increased pulmonary blood flow, *May*, 282

Blood vessels (*Continued*)
great, transposition, with ventricular septal defect and interatrial communication, *Feb.*, 88
pulmonary, disease, occlusive, atrial septal defect with, *Feb.*, 80
ventricular septal defect with, *Feb.*, 80
with corrected transposition of great vessels and ventricular septal defect, *Feb.*, 80
with patent ductus arteriosus, *Feb.*, 82
in congenital heart disease, *Feb.*, 128
Bones, roentgen findings in cystic fibrosis of pancreas, *Feb.*, 166–7
Bowel. See *Intestines.*
Bradycardia, sinus, *May*, 318–19
Brain. See also *Nervous system.*
diseases, fluid therapy in, *Feb.*, 12–13
Breathing. See also *Respiration.*
exercises in cystic fibrosis of pancreas, *Feb.*, 145
Bronchodilators in cystic fibrosis of pancreas, *Feb.*, 145
Bundle branch block, death in myocarditis due to, *May*, 419, 420
Burns, fluid therapy in, *Feb.*, 12

CALCIUM, in diarrhea, *Feb.*, 7
Calcium chloride
in cardiac arrest, *May*, 355
in hypertension, *May*, 452
Calcium gluconate
during exchange transfusion, *May*, 376
in hyperkalemic glomerulonephritis, *Aug.*, 643
in postacidotic tetany, *Feb.*, 5
Capillaries. See also *Blood vessels.*
glomerular, thrombosis of, *Aug.*, 540–41
Cardiac. See *Heart.*
Cardiovascular complications of glomerulonephritis, treatment, *Aug.*, 641–2
Cardiovascular disorders of newborn, *May*, **363–400**
Cardiovascular system. See also *Arteries; Blood vessels; Heart; Veins;* etc.
action of digitalis on, *May*, 232–5
consequences of birth asphyxia, *May*, 369–73
lesions, hypertension due to, *May*, 445–6
problems incident to erythroblastosis, *May*, 374–7
Cardiovascular therapy, symposium on, *May*, **211–495**
Cardioversion in atrial fibrillation, *May*, 333
Carditis, rheumatic. See *Rheumatic carditis.*
Catheterization of bladder, bacteriuria and, *Aug.*, 747–8
Catheters, urinary, dangers of, *Feb.*, 43
Cedilanid. See *Deslanoside.*
Chelating agents in cardiac arrhythmias, *May*, 359
Chemotherapeutic agents, susceptibility of urinary pathogens to, *Aug.*, 524–5
Chemotherapy. See also specific agents.
adjunct, for nephroblastoma, *Feb.*, 39–40
Children. See also *Infants; Newborn.*
heart failure in, *May*, 255–6
Chloramphenicol in staphylococcal endocarditis, *May*, 490, 493
Chloride in respiratory distress syndrome, *May*, 381
Chlorothiazide (Diuril)
in heart failure, *May*, 265
in hypertension, *May*, 455
Chlorpromazine (Thorazine) in cardiac arrhythmias, *May*, 358
Chromosomes
abnormalities, clinical effects of, *Feb.*, 175–81
of number, *Feb.*, 172
psychologic aspects, *Feb.*, 181
current knowledge, *Feb.*, **171–82**
mosaicism, *Feb.*, 172, 173, 180
non-disjunction, *Feb.*, 172
translocation, *Feb.*, 174, 180
trisomy, *Feb.*, 172
D, *Feb.*, 178–9
E, *Feb.*, 178–9
syndromes, *Feb.*, 176–7
XXX, *Feb.*, 177
XXY, *Feb.*, 177–8
XYY, *Feb.*, 178
13–15, *Feb.*, 178–9
17–18, *Feb.*, 178–9
Circulation. See under *Blood.*
Cleft palate. See *Palate, cleft.*
Climate in cystic fibrosis of pancreas, *Feb.*, 145
Clinical advances. See *Advances, clinical.*
Coarctation
of aorta. See *Aorta, coarctation.*
of pulmonary arteries, *Feb.*, 115
Cold, common, immunity to, *Feb.*, 21–2
Colon. See also *Gastrointestinal tract; Intestines;* etc.
roentgen findings in cystic fibrosis of pancreas, *Feb.*, 162–6
Common cold, immunity to, *Feb.*, 21–2
Conduction. See under *Heart.*

Cor pulmonale, acute, with meconium aspiration pneumonia, *May*, 397–8
Cor triatriatum, treatment, *May*, 307
Cor triloculare, *Feb.*, 114–15
Cor triloculare biatriatum, *Feb.*, 86
Cor triloculare biventriculare, *May*, 278–9
Coronary arteries. See *Arteries, coronary.*
Coronary circulation, effect of digitalis on, *May*, 235
Coronary sinus
  anomalous communication of coronary artery with, *Feb.*, 62
  rhythm, *May*, 320
Corticosteroids in rheumatic fever, *May*, 218, 219, 221
Cortisone
  hypertension due to, *May*, 446
  in rheumatic fever, *May*, 221
Cow's milk, allergy to, *Feb.*, 22–7
C-reactive protein in rheumatic fever, *May*, 221
Crista supraventricularis, ventricular septal defect inferior to, *Feb.*, 74
Cryptorchidism, surgical advances in, *Feb.*, 41
Cushing's syndrome
  hypertension due to, *May*, 447
    surgical treatment, *May*, 459
Cyanosis, *Feb.*, 56
  congenital anomalies of heart and great vessels with, *Feb.*, 78–101
  congenital anomalies of heart and great vessels without, *Feb.*, 58–77
Cystic fibrosis, *Feb.*, 139–69
  abnormal secretions, *Feb.*, 150
  aerodynamic considerations, *Feb.*, 146–7
  impaired mucus drainage, *Feb.*, 150
  mechanics of respiration in, *Feb.*, 147, 150
  shock from, fluid therapy in, *Feb.*, 11–12
Cystic teratoma of ovary, *Feb.*, 52

DEATH
  in myocarditis, causes, *May*, 410–23
  perinatal, in bacteriuric pregnant women, *Aug.*, 749
Defect, septal. See *Atrial septal defect; Ventricular septum, defect.*
Defibrillator in cardiac arrest, *May*, 355
Deformities. See *Abnormalities.*
Dehydration, *Feb.*, 4
  hypertonic, fluid therapy in, *Feb.*, 9
  hypotonic, fluid therapy in, *Feb.*, 9
  in newborn, *Feb.*, 10
  in premature infants, *Feb.*, 10
Dehydration (*Continued*)
  moderate, fluids for, *Feb.*, 4, 5
Demerol. See *Meperidine.*
Deslanoside (Cedilanid), *May*, 238
  dosage, *May*, 241
  in cardiac arrhythmias, *May*, 359
Diabetes mellitus, pyelonephritis and, *Aug.*, 750
Diabetic acidosis, fluid therapy in, *Feb.*, 10
Dialysis. See also *Hemodialysis.*
  peritoneal, *Aug.*, **593–609**
    advantages, *Aug.*, 597
    clinical application, *Aug.*, 598
    comparison with hemodialysis, *Aug.*, 596–9
    complications, *Aug.*, 603–604
    current scope, *Aug.*, 596–604
    disadvantages, *Aug.*, 597, 598
    effects, *May*, 458
    for infants and small children, *Aug.*, 603
    in glomerulonephritis, *Aug.*, 643, 644
    indications for, *Aug.*, 599–603
    modifications, *Aug.*, 604–605
    solutions, *Aug.*, 594
      modification of, *Aug.*, 604–605
    techniques, *Aug.*, 594–6
      modification of, *Aug.*, 605
Diamox. See *Acetazolamide.*
Diaphragm, hernia, surgical advances in, *Feb.*, 37
Diarrhea
  acidosis in, *Feb.*, 6–7
  fluid therapy, *Feb.*, 4–8
  shock in, *Feb.*, 6
Diet. See also *Nutrition; Vitamins.*
  in cystic fibrosis of pancreas, *Feb.*, 145
  in renal acid-base disorders, *Aug.*, 626
Digestion, disturbances of, in cystic fibrosis of pancreas, treatment, *Feb.*, 145–6
Digilanid, dosage, *May*, 241
Digitalis, *May*, 238
  action, mechanism of, *May*, 231–2
  chemistry, *May*, 229–30
  dosage, *May*, 258
  electrocardiographic effects, *May*, 234
  excretion, *May*, 241–2
  fate, *May*, 241–2
  for heart failure in rheumatic fever, *May*, 222–3
  glycosides, structural differences, *May*, 230
  in atrial fibrillation, *May*, 333
  in atrial flutter, *May*, 332
  in cardiac arrhythmias, *May*, 356–7, 359
  in cyanotic congenital heart disease, *May*, 286–7

Digitalis (*Continued*)
in heart failure, *May*, 256–60
maintenance therapy, *May*, 260–61
in myocarditis, *May*, 412
in paroxysmal tachycardia, *May*, 357
in respiratory distress syndrome, *May*, 381
in supraventricular tachycardia, *May*, 328, 329, 357
pharmacologic effects, *May*, 232–6
pharmacology, *May*, **229–45**
preparations, *May*, 238
choice of, *May*, 264
doses, *May*, 241
for pediatric use, *May*, 257
source, *May*, 229–30
structure-activity relationship, *May*, 230–31
therapeutic indications for, *May*, 242
toxicity, *May*, 236–8, 261–4
antagonism of, *May*, 237–8
treatment, *May*, 263
Digitoxin, *May*, 238
dosage, *May*, 241
in cardiac arrhythmias, *May*, 359
in heart failure, *May*, 257, 258, 259, 260
Digoxin (Lanoxin), *May*, 238
dosage, *May*, 241
for heart failure in rheumatic fever, *May*, 222
in cardiac arrhythmias, *May*, 359
in cyanotic congenital heart disease, *May*, 287
in erythroblastosis fetalis, *May*, 376
in heart failure, *May*, 257, 258, 259, 260
in respiratory distress syndrome, *May*, 386
Disease. See also *Death*.
glycogen storage, of heart, *Feb.*, 113
Hirschsprung's, surgical advances in, *Feb.*, 38–9
Diuresis and diuretics
in cardiac arrhythmias, *May*, 358, 359
in glomerulonephritis, *Aug.*, 644
in heart failure, *May*, 264, 265
Diuretic effects of digitalis, *May*, 235–6
Diuril. See *Chlorothiazide*.
Down's syndrome, *Feb.*, 179–80
Drainage
postural, in cystic fibrosis of pancreas, *Feb.*, 145
total anomalous, of pulmonary veins, *Feb.*, 129–30
Drugs, therapy. See also *Chemotherapy;* and under names of drugs.
in cardiac arrhythmias, *May*, 356–61
in hypertension, dosage and toxicity, *May*, 455
Ductus arteriosus
closed, and intact ventricular septum, transposition of great vessels with, *Feb.*, 90
subpulmonary stenosis and intact ventricular septum, with transposition of great vessels, *Feb.*, 90
patent, *Feb.*, 117–18, 135; *May*, 305–306
and interatrial communication, with transposition of great vessels, *Feb.*, 88
and ventricular septal defect, interruption of aortic arch proximal to, *Feb.*, 82
classic, *Feb.*, 66
complicating ventricular septal defect, *Feb.*, 120
wide, *Feb.*, 74
with occlusive pulmonary vascular disease, *Feb.*, 82
with atrial septal defect, *Feb.*, 122
Dysautonomia, familial, hypertension due to, *May*, 445
Dysgenesis, gonadal, *Feb.*, 175

EBSTEIN'S anomaly, *Feb.*, 132; *May*, 279
Ebstein's malformation, *Feb.*, 98
treatment, *May*, 307
Eczema, steroid therapy in, *Feb.*, 20, 21
Edema in heart failure, *May*, 251
Eisenmenger's syndrome, *Feb.*, 133
Electrocardiogram. See *Heart, electrocardiography*.
Emboli, death in myocarditis due to, *May*, 414–15
Emphysema in cystic fibrosis of pancreas, *Feb.*, 150
Endocarditis
bacterial, *May*, **483–95**
enterococcal, *May*, 490
fungal, *May*, 491
staphylococcal, *May*, 489–90
Streptococcus viridans, *May*, 487–9
Endocardium
fibroelastosis, *Feb.*, 113; *May*, 402 ff.
causes of death in, *May*, 411
of left ventricle, treatment, *May*, 308
surgical treatment, *May*, 428
ventricular, left, *Feb.*, 113
Endocrine disorders, hypertension due to, *May*, 446–8
Endocrine system, roentgen findings in cystic fibrosis of pancreas, *Feb.*, 167
Endomyocardial disease, primary, *May*, **401–30**
Endotoxin, effects in urinary tract infections, *Aug.*, 529

Enterococci, endocarditis, *May*, 490
Enzymes, pancreatic, in cystic fibrosis, *Feb.*, 145
Ephedrine sulfate
  in cardiac arrhythmias, *May*, 360
  in heart block, *May*, 347
Epinephrine
  for edema in myocarditis, *May*, 413
  in cardiac arrest, *May*, 355
  in left ventricular failure due to shunts, *May*, 266
  in Stokes-Adams syndrome, *May*, 348
Erythroblastosis. See *Hemolytic disease of newborn.*
Erythromycin
  in staphylococcal endocarditis, *May*, 490, 493
  in streptococcal infections, *May*, 227
  prophylaxis against bacterial endocarditis, *May*, 492
Erythropoiesis and anemia in renal disease, *Aug.*, 667–73
Erythropoietin production in kidney, *Aug.*, 670
Escherichia coli in urinary tract infection, *Aug.*, 519, 520
Esophagus
  atresia, surgical advances in, *Feb.*, 36
  replacement with other visceral tubes, *Feb.*, 41
Examination, physical. See *Physical examination.*
Exercises, breathing, in cystic fibrosis of pancreas, *Feb.*, 145
Exhaustion, heat, fluid therapy in, *Feb.*, 12
Expectorants in cystic fibrosis of pancreas, *Feb.*, 145
Exstrophy of bladder, surgical advances in, *Feb.*, 40–41
Extrasystoles, *May*, 323–4
  due to digitalis toxicity, *May*, 262
  ventricular, *May*, 334–8
    due to digitalis, *May*, 236

FALLOT, tetralogy of. See *Tetralogy of Fallot.*
Familial dysautonomia, hypertension due to, *May*, 444, 445
Feces. See also *Meconium.*
  in cystic fibrosis of pancreas, *Feb.*, 142
Feeding. See also *Diet.*
  difficulty in acyanotic congenital heart disease, *May*, 297
Feminization, testicular, *Feb.*, 49
Fetus. See also *Infants; Newborn.*
  circulation, *May*, 364–8
Fever, fluids for, *Feb.*, 5
Fibrillation
  atrial, *May*, 332–4
  flutter, *May*, 332
  ventricular, *May*, 340–41
Fibroelastosis, endocardial. See *Endocardium, fibroelastosis.*
Fibrosis, cystic. See *Cystic fibrosis.*
Fistula
  arteriovenous, pulmonary, *Feb.*, 100
  of sinus of Valsalva, *Feb.*, 119
Fluids
  restriction in heart failure, *May*, 265
  therapy, *Feb.*, **3–15**
    in adrenocortical insufficiency, *Feb.*, 11
    in anuria, *Feb.*, 12
    in aspirin poisoning, *Feb.*, 11
    in burns, *Feb.*, 12
    in diabetic acidosis, *Feb.*, 10
    in diarrhea, *Feb.*, 4–8
      basic fluids, *Feb.*, 5–6
      first day, *Feb.*, 7–8
      oral fluids, *Feb.*, 8
      rate of administration, *Feb.*, 5
    in heat exhaustion, *Feb.*, 12
    in hypertonic dehydration, *Feb.*, 9
    in hypotonic dehydration, *Feb.*, 9
    in moderate dehydration, *Feb.*, 4, 5
    in newborn, *Feb.*, 10
    in premature infants, *Feb.*, 10
    in shock, *May*, 473–4
      from cystic fibrosis, *Feb.*, 11–12
    in surgical patients, *Feb.*, 9–10
    in vomiting, *Feb.*, 11
    in water intoxication, *Feb.*, 9
    maintenance, *Feb.*, 9–10
    parenteral administration, indications for, *Feb.*, 13
      mode of, *Feb.*, 13–14
    postoperative, in cyanotic congenital heart disease, *May*, 287–8
Flutter
  atrial, *May*, 331–2
  fibrillation, *May*, 332
Foramen ovale, patent, and intact ventricular septum, with pulmonary stenosis, *Feb.*, 96
Foreign bodies in vagina, *Feb.*, 50–51
Fossa ovalis
  atrial septal defect at, *Feb.*, 60
  atrial septal defect superior to, *Feb.*, 79
Fungi, endocarditis due to, *May*, 491

GALLBLADDER. See also *Biliary tract.*
  roentgen findings in cystic fibrosis of pancreas, *Feb.*, 166
Ganglion blockers in hypertension, *May*, 454

Gastric. See *Stomach.*
Gastrointestinal tract. See also *Colon; Intestines; Stomach;* etc.
digitalis toxicity and, *May,* 236
effects of digitalis on, *May,* 235
in cystic fibrosis of pancreas, *Feb.,* 141–3
roentgen findings, *Feb.,* 158–66
treatment, *Feb.,* 145–6
Genitals. See also *Gonads; Urinary tract.*
female, external, trauma to, *Feb.,* 54
Gitalin, *May,* 238
dosage, *May,* 241
in cardiac arrhythmias, *May,* 359
Glands. See specific glands.
Glenn's shunt, *May,* 282–3
for Ebstein's anomaly, *May,* 279
Glomerulonephritis. See *Nephritis, glomerular.*
Glucose
in dehydration, *Feb.,* 5
in hyperkalemic glomerulonephritis, *Aug.,* 643
in renal acid-base disorders, *Aug.,* 627
Glycogen storage disease of heart, *Feb.,* 113
Glycol, propylene
for airway obstruction in pneumonia complicating acyanotic congenital heart disease, *May,* 312
in cystic fibrosis of pancreas, *Feb.,* 144
Glycosides. See also *Digitalis;* etc.
action, *May,* 239, 240
administration, route of, *May,* 239
differences between, *May,* 238–41
dosage, *May,* 239–40, 241
lactone ring, *May,* 231
of digitalis, structural differences, *May,* 230
steroid nucleus, *May,* 231
sugar linkage, *May,* 230
Gonads. See also *Genitals; Hermaphroditism; Ovary; Testes.*
agenesis, hypertension due to, *May,* 448
dysgenesis, *Feb.,* 175
Goodpasture's syndrome, immunologic processes in, *Aug.,* 707
Griess nitrite test, *Aug.,* 523
Growth. See also *Diet; Nutrition;* etc.
aberrations in renal disease, *Aug.,* **563–75**
failure, due to chronic acidosis, *Aug.,* 564–7
in acyanotic heart disease, *May,* 297
retardation, relation to albuminuria, *Aug.,* 569–70
relation to aminoaciduria, *Aug.,* 569–70
Growth (*Continued*)
retardation, relation to azotemia, *Aug.,* 567
relation to reduced renal concentrating ability, *Aug.,* 568
relation to renal osteodystrophy, *Aug.,* 568–9
relation to undernutrition, *Aug.,* 567–8
relation to vitamin D-refractory rickets, *Aug.,* 569
Gynecologic surgery, *Feb.,* **45–54**

HEART. See also *Arrhythmias; Arteries, coronary; Blood, circulation; Cardiovascular system;* etc.
arrest, *May,* 353–6
arrhythmias. See *Arrhythmias.*
atresia, of left side of, *Feb.,* 129–30
of right side of, *Feb.,* 127
beat, interference, *May,* 342
premature. See *Extrasystoles.*
block, *May,* 341–51
complete, *May,* 345–8
death in myocarditis due to, *May,* 417
incomplete, *May,* 344–5
postoperative, in cyanotic congenital heart disease, *May,* 289–90
right bundle branch block, *May* 348–50
sinoatrial, *May,* 341–2
conduction, accelerated, *May,* 351–2
with short P-R interval, *May,* 352
disturbances, death in myocarditis due to, *May,* 416–21
conduction system, *May,* 315–16
conduction time, effect of digitalis on, *May,* 233
congenital anomalies, *Feb.,* 55–105
contractility, effect of digitalis on, *May,* 232–3
cor pulmonale, acute, *May,* 397–8
cor triatriatum, treatment, May, 307
cor triloculare, *Feb.,* 114–15
cor triloculare biatriatum, *Feb.,* 86
cor triloculare biventriculare, May, 278–9
digitalis toxicity and, *May,* 236–7
disease, congenital, acyanotic, *May,* **295–314**
clinical considerations, *Feb.,* 107–10
cyanotic, *May,* **269–94**
diagnosis, *Feb.,* 109, 110
differential diagnosis, *Feb.,* **107–38**
fool's guide to diagnosis, *Feb.,* **134–5**

Heart (*Continued*)
disease, congenital, lesions with decreased pulmonary vascularity, *Feb.*, 130–32
lesions with increased pulmonary vascularity, *Feb.*, 132–4
lesions with left-to-right shunt, *Feb.*, 117–24
lesions with no shunt, *Feb.*, 110–17
lesions with right-to-left shunt, *Feb.*, 124–34
pulmonary vasculature in, *Feb.*, 128
fluid therapy in, *Feb.*, 12–13
glycogen storage, *Feb.*, 113
rheumatic. See *Rheumatic heart disease.*
dysfunction, in acyanotic congenital heart disease, *May*, 300–306
Eisenmenger's syndrome, *Feb.*, 133
electrocardiography, effect of digitalis on, *May*, 234
in accelerated conduction with short P-R interval, *May*, 352
in acyanotic congenital heart disease, *May*, 299, 300
in atrioventricular block, *May*, 344
in bundle branch block, *May*, 349
in cardiac arrest, *May*, 354
in complete heart block, *May*, 347
in coronary sinus rhythm, *May*, 320
in extrasystoles, *May*, 323
in heart failure, *May*, 254, 255
in nodal rhythm, *May*, 344
in paroxysmal atrial tachycardia with block, *May*, 331
in sinoatrial block, *May*, 342
in sinus arrhythmia, *May*, 320
in sinus bradycardia, *May*, 319
in sinus tachycardia, *May*, 317
in supraventricular tachycardia, *May*, 327
in ventricular fibrillation, *May*, 341
in ventricular premature beats, *May*, 336–7
in ventricular tachycardia, *May*, 338–9
in wandering pacemaker, *May*, 322
in Wenckebach's phenomenon, *May*, 351
in Wolff-Parkinson-White syndrome, *May*, 352
enlargement, in acyanotic congenital heart disease, *May*, 299
failure. See *Heart, arrest; Heart, insufficiency.*
insufficiency, *May*, **247–67**
congestive, *Feb.*, 128
in bacterial endocarditis, *May*, 485, 486
Heart (*Continued*)
insufficiency, congestive, with left-to-right shunt, *May*, 312
death in myocarditis due to, *May*, 411–13
in childhood, *May*, 255–6
in glomerulonephritis, treatment, *Aug.*, 642
in infancy, *May*, 247–55
in rheumatic fever, *May*, 222–3
left-to-right shunts, *May*, 303–306
malformations, left-sided, *May*, 300–303
right-sided, *May*, 300
massage, for birth asphyxia, *May*, 370
in cardiac arrest, *May*, 355
murmurs and sounds, in acyanotic congenital heart disease, *May*, 298–9
in heart failure, *May*, 249, 250
myxoma, *Feb.*, 115
output, effect of digitalis on, *May*, 233
pacemaker, wandering, *May*, 321–2
postoperative maintenance of, in cyanotic congenital heart disease, *May*, 286
pseudotruncus arteriosus, *Feb.*, 92, 130
rate, effect of digitalis on, *May*, 233–4, 237
in heart failure, *May*, 249, 250
sinus bradycardia, *May*, 318–19
refractory period, effect of digitalis on, *May*, 233
size, in congenital heart disease, *Feb.*, 128, 129
in heart failure, *May*, 249
sounds. See *Heart, murmurs and sounds.*
Taussig-Bing syndrome, *Feb.*, 84, 133
Heat. See also *Burns; Temperature.*
exhaustion, fluid therapy in, *Feb.*, 12
Heiner's syndrome, *Feb.*, 27–30
Hematocolpos, *Feb.*, 47
Hematologic aspects of renal disease, *Aug.*, **667–84**
Hemodialysis. See also *Dialysis, peritoneal.*
comparison with peritoneal dialysis, *Aug.*, 596–9
Hemolysis. See also *Anemia, hemolytic.*
in renal disease, *Aug.*, 671
thrombocytopenia and nephropathy, syndrome of, *Aug.*, 675–81
Hemolytic disease of newborn, cardiovascular problems incident to, *May*, 374–7
Hemolytic-uremic syndrome, *Aug.*, 543, 577–91
diagnosis, *Aug.*, 588
etiology, *Aug.*, 586
immunologic processes in, *Aug.*, 708

Hemolytic-uremic syndrome (*Continued*)
pathogenesis, *Aug.*, 586
pathologic changes, *Aug.*, 586
treatment, *Aug.*, 589
Hemopericardium, postoperative, *May*, 286
Hemorrhage. See also *Purpura.*
acute, in newborn, *May*, 374
postoperative, in cyanotic congenital heart disease, *May*, 290
Hermaphroditism
intersex problem, *Feb.*, 47–50
corrective procedures, *Feb.*, 49–50
male, *Feb.*, 48–9
true, *Feb.*, 48
Hernia
diaphragmatic, surgical advances in, *Feb.*, 37
inguinal, *Feb.*, 42
Hirschsprung's disease, surgical advances in, *Feb.*, 38–9
History
in acyanotic congenital heart disease, *May*, 296–8
in cardiac failure in infancy, *May*, 249
Hormones, adrenocortical, in shock, *May*, 477–9
Host defenses to viral infection, *Aug.*, 550
Humidifiers in cystic fibrosis of pancreas, *Feb.*, 144
Humidity, postoperative, in cyanotic congenital heart disease, *May*, 286
Hyaline membrane disease. See *Respiratory distress syndrome.*
Hydralazine hydrochloride (Apresoline)
in hypertension, *May*, 453 ff.
in hypertensive glomerulonephritis, *Aug.*, 642
Hydrochlorothiazide in heart failure, *May*, 265
Hydrocortisone, hypertension due to, *May*, 446
Hydrometrocolpos, *Feb.*, 47
Hydrops fetalis, *May*, 374, 375
Hydroxyzine hydrochloride (Atarax)
in cardiac arrhythmias, *May*, 358
in supraventricular tachycardia, *May*, 329
Hymen, imperforate, *Feb.*, 47
Hyperelectrolytemia, *Feb.*, 4
Hyperplasia, adrenal, congenital, *Feb.*, 46–7
Hypersensitivity, diseases of, *Aug.*, 541–4
Hypertension, *May*, 431–63
amenable to surgical treatment, *May*, 458
and renal disease, *Aug.*, **723–30**
essential, *May*, 449
etiology, *Aug.*, 724
Hypertension (*Continued*)
in glomerulonephritis, treatment, *Aug.*, 641–2
pulmonary. See *Pulmonary hypertension.*
pyelonephritis and, *Aug.*, 749–50
renal, diagnosis, *Aug.*, 725
pathogenesis, *Aug.*, 727
surgical conditions, *May*, 458–62
systemic, *May*, **431–63**
with pyelonephritis, *Aug.*, 661
Hyperthyroidism, hypertension due to, *May*, 448
Hypertonic dehydration, fluid therapy in, *Feb.*, 9
Hypertrophy, ventricular. See *Ventricular hypertrophy.*
Hypodermoclysis, *Feb.*, 13
Hyponatremia, *Feb.*, 9
Hypothermia in shock, *May*, 474–5
Hypotonic dehydration, fluid therapy in, *Feb.*, 9

IATROGENIC causes of death in myocarditis, *May*, 423
Ileus. See *Intestines, obstruction; Meconium.*
meconium. See *Meconium ileus.*
Immune response
and bacteriology in urinary tract infections, *Aug.*, **517–31**
in urinary tract infection, *Aug.*, 528–9
Immunity, *Aug.*, 549
and resistance to virus infections, mechanisms of, *Aug.*, **549–61**
in viral infections, proposed mechanisms, *Aug.*, 555–8
to common cold, *Feb.*, 21–2
Immunoglobulins, *Aug.*, 552
physicochemical properties, *Aug.*, 553
Immunologic basis of renal disease, *Aug.*, **685–721**
Immunologic mechanisms, renal disease due to, *Aug.*, 699–711
Immunologic processes in renal diseases, *Aug.*, 702–708
Immunologic renal diseases, experimental, *Aug.*, 685–98
Infants. See also *Children; Newborn.*
heart failure in, *May*, 247–55
Infarction, myocardial, death in myocarditis due to, *May*, 415–16
Infection. See also *Bacteremia; Immunity.*
accompanying medical shock, *May*, 466–9
in heart failure, treatment, *May*, 266
streptococcal. See *Streptococci, infection.*
urinary tract. See under *Urinary tract.*

Inguinal hernia, *Feb.*, 42
Insulin. See also *Pancreas.*
in diabetic acidosis, *Feb.*, 10
in hyperkalemic glomerulonephritis, *Aug.*, 643
in respiratory distress syndrome, *May*, 388
Interatrial communication
and patent ductus arteriosus, with transposition of great vessels, *Feb.*, 88
and ventricular septal defect with transposition of great vessels, *Feb.*, 88
Interference beat; interference dissociation, *May*, 342
Interferon, *Aug.*, 551–2
role in recovery from virus infection, *Aug.*, 555, 556
Intersex. See under *Hermaphroditism.*
Intestines. See also *Colon; Feces; Gastrointestinal tract*, etc.
obstruction, in cystic fibrosis of pancreas, *Feb.*, 141
surgical advances in, *Feb.*, 37–8
small, roentgen findings in cystic fibrosis of pancreas, *Feb.*, 162
Intussusception, surgical advances in, *Feb.*, 39
Irritability in acyanotic congenital heart disease, *May*, 297
Isoprenaline hydrochloride (Saventrine) in heart block, *May*, 347
Isoproterenol (Isuprel)
in cardiac arrest, *May*, 356
in cardiac arrhythmias, *May*, 360, 361
in conduction disturbances, *May*, 421
in heart block, *May*, 347
Isosthenuria, relation to growth retardation, *Aug.*, 568
Isuprel. See *Isoproterenol.*

KIDNEYS. See also *Urinary tract.*
acid-base disorders, *Aug.*, **611–32**
treatment, *Aug.*, 626–9
acidosis, *Aug.*, 614–22
alkalosis, *Aug.*, 622–6
cortical necrosis, *Aug.*, 544
development, current concepts, *Aug.*, **759–66**
disease, anemia in, *Aug.*, 667–73
antigen-antibody-complex, *Aug.*, 685–9
pathogenesis, *Aug.*, 709
autoimmune, *Aug.*, 694–6
pathogenesis, *Aug.*, 709–10
Kidneys (*Continued*)
disease, bleeding abnormalities in, *Aug.*, 673–4
due to immunologic mechanisms, *Aug.*, 699–711
due to viruses, *Aug.*, 558–9
erythropoiesis in, *Aug.*, 667–73
experimental, relation to human renal disease, *Aug.*, 698–9
role of streptococci in, *Aug.*, 696–8
fluid therapy in, *Feb.*, 12–13
growth aberrations in, *Aug.*, **563–75**
hematologic aspects, *Aug.*, **667–84**
hemolytic anemia and thrombocytopenia, *Aug.*, **577–91**
hypertension and, *May*, 435–44; *Aug.*, 723–30
surgical treatment, *May*, 459 ff.
immunologic, experimental, *Aug.*, 685–98
pathogenesis, *Aug.*, 709–11
immunologic basis, *Aug.*, **685–721**
immunologic processes in, *Aug.*, 702, 708
nephrotoxic-serum, *Aug.*, 689–94
produced by injection of kidney, *Aug.*, 694–6
relation to experimental renal disease, *Aug.*, 698–9
disorders, symposium on, *Aug.*, **515–766**
failure. See *Kidneys, insufficiency.*
function, in pyelonephritis, *Aug.*, 656–63
function test, split, *May*, 443
glomerular capillaries and arterioles, thrombosis of, *Aug.*, 540–41
hypoplastic, hypertension due to, *May*, 444
infection, reflux, *Aug.*, 653–6
injection of, renal disease produced by, *Aug.*, 694–6
insufficiency, acute, hypertension due to, *May*, 444
in glomerulonephritis, treatment, *Aug.*, 642–4
osteodystrophy, relation to growth retardation, *Aug.*, 568–9
reduced concentrating ability, growth retardation due to, *Aug.*, 568
thrombosis, *Aug.*, 533–41
tumors, nephroblastoma, *Feb.*, 39–40
Wilms's, *Feb.*, 39
hypertension due to, *May*, 444
vascular disease, *Aug.*, **533–47**
hypertension due to, *May*, 441 ff.
veins, thrombosis of, *Aug.*, 534–7
Klinefelter's syndrome, *Feb.*, 176, 177–8

LABORATORY studies in heart failure, *May*, 252–5
Lactate in respiratory distress syndrome, *May*, 381
Lactone ring of glycosides, *May*, 231
Lanatoside C in heart failure, *May*, 257, 258, 259, 260
Lanoxin. See *Digoxin*.
Lead poisoning, hypertension due to, *May*, 449
Levarterenol bitartrate (Levophed). See also *Norepinephrine*.
  in cardiac arrest, *May*, 355
  in cardiac arrhythmias, *May*, 358
Levophed. See *Levarterenol bitartrate; Norepinephrine*.
Lidocaine (Xylocaine)
  in cardiac arrhythmias, *May*, 360
  in supraventricular tachycardia, *May*, 328
  in ventricular extrasystoles, *May*, 337
Liver. See also *Biliary tract*.
  diseases, fluid therapy in, *Feb.*, 12–13
  enlargement, in heart failure, *May*, 251
Lungs. See also *Respiration; Respiratory tract*.
  diseases, fluid therapy in, *Feb.*, 12–13
  infections, effect on acyanotic congenital heart disease, *May*, 310–11
  insufflation, in respiratory distress syndrome, *May*, 390
Lupus erythematosus, renal manifestations, *Aug.*, 541–2
Lupus nephritis, immunologic processes in, *Aug.*, 704

MAGNESIUM sulfate
  in hypertension, *May*, 452, 455
  in hypertensive glomerulonephritis, *Aug.*, 642
  in supraventricular tachycardia, *May*, 328
Malformations. See *Abnormalities;* and under organs and regions.
Massage, cardiac. See *Heart, massage*.
Mecholyl. See *Methacholine*.
Meconium aspiration pneumonia with acute cor pulmonale, *May*, 397–8
Meconium ileus
  in cystic fibrosis of pancreas, *Feb.*, 141
    roentgen findings, *Feb.*, 158–62
    treatment, *Feb.*, 145
  surgical advances in, *Feb.*, 37
Medical research today, *Feb.*, 17–18
Medical shock. See *Shock, medical*.
Megacolon, aganglionic, *Feb.*, 38
Membrane, mitral, supravalvular, treatment, *May*, 308
Meperidine (Demerol)
  in cardiac arrhythmias, *May*, 358
  in supraventricular tachycardia, *May*, 328
  in ventricular tachycardia, *May*, 340
Mephentermine (Wyamine)
  in cardiac arrhythmias, *May*, 358
  in ventricular tachycardia, *May*, 340
Meralluride (Mercuhydrin)
  in cardiac arrhythmias, *May*, 358
  in heart failure, *May*, 265
Mercaptomerin (Thiomerin) in cardiac arrhythmias, *May*, 358
Mercuhydrin. See *Meralluride*.
Mercury poisoning, hypertension due to, *May*, 449
Metaramine (Aramine)
  in cardiac arrhythmias, *May*, 358
  in supraventricular tachycardia, *May*, 329
  in ventricular tachycardia, *May*, 340
Methacholine (Mecholyl) in supraventricular tachycardia, *May*, 329
Milk, cow's, allergy to, *Feb.*, 22–7
Mist tents in cystic fibrosis of pancreas, *Feb.*, 144–5
Mitral membrane, supravalvular, treatment, *May*, 308
Mitral valve
  atresia, *Feb.*, 129
    and subpulmonary stenosis with common ventricle, *Feb.*, 94
    with common ventricle and transposed great vessels, *Feb.*, 86
  cleft, atrial septal defect associated with, *Feb.*, 60
  lesions, *Feb.*, 114–15
  stenosis, congenital, *Feb.*, 114
    treatment, *May*, 308
Mongolism. See *Down's syndrome*.
Morphine sulfate
  in cardiac arrhythmias, *May*, 358
  in heart failure, *May*, 265
  in supraventricular tachycardia, *May*, 328
  in ventricular tachycardia, *May*, 340
  postoperative, in cyanotic congenital heart disease, *May*, 288
Mosaicism, chromosomal, *Feb.*, 172, 173, 180
Mucoantibody, *Aug.*, 554–5
Mucus, impaired drainage, in cystic fibrosis of pancreas, *Feb.*, 150
Murmurs, cardiac. See *Heart, murmurs and sounds*.
Myocarditis, *May*, 401–30
Myocarditis-endocardial fibroelastosis syndrome, *May*, **401–30**

Myocardium
infarction, death in myocarditis due to, *May*, 415–16
ventricular, left, *Feb.*, 113
Myxoma, cardiac, *Feb.*, 115

NECK roentgenograms, exposure values for, *Feb.*, 187
Necrosis, cortical, renal, *Aug.*, 544
Neonatal. See *Newborn.*
Neostigmine (Prostigmin)
in cardiac arrhythmias, *May*, 360
in supraventricular tachycardia, *May*, 328
Neo-Synephrine. See *Phenylephrine hydrochloride*
Nephritis. See also *Albuminuria; Kidneys, disease; Kidneys, insufficiency; Pyelonephritis; Uremia.*
anaphylactoid, immunologic processes in, *Aug.*, 707
chronic, *Aug.*, 646
familial, history of, significance, *Aug.*, 647
glomerular, acute, hypertension due to, *May*, 435 ff.
chronic, hypertension due to, *May*, 439
immunologic processes in, *Aug.*, 707
hypertension due to, treatment, *May*, 452–7
poststreptococcal, *Aug.*, **633–48**
clinical features, *Aug.*, 636–7
convalescence, *Aug.*, 645–6
diagnosis, criteria of, *Aug.*, 646
epidemiology, *Aug.*, 634–5
immunologic processes in, *Aug.*, 703
incidence, *Aug.*, 635
natural history, *Aug.*, 633–4
pathology, *Aug.*, 637–41
site of infection, *Aug.*, 635
treatment, *Aug.*, 641–7
subacute, immunologic mechanisms in, *Aug.*, 704
hypertension due to, *May*, 439
treatment, *May*, 452–7
lupus, immunologic processes in, *Aug.*, 704
Nephroblastoma, chemotherapy for, *Feb.*, 39–40
Nephrons, formation, *Aug.*, 760
Nephropathy, hemolysis and thrombocytopenia, syndrome of, *Aug.*, 675–81
Nephrotic syndrome
idiopathic, immunologic processes in, *Aug.*, 708–709
Nephrotic syndrome (*Continued*)
vs. nephrosis, *Aug.*, 644
Nephrotoxic-serum renal disease, *Aug.*, 689–94
Nervous system. See also *Brain.*
central, disorders of, hypertension due to, *May*, 445–6
digitalis toxicity and, *May*, 237
Neuraminidase, *Aug.*, 550
Neuroblastoma, surgical advances in, *Feb.*, 40
Newborn
cardiovascular disorders, *May*, **363–400**
dehydration in, *Feb.*, 10
fluid therapy in, *Feb.*, 10
heart failure in, *Feb.*, 128
hemolytic disease of, cardiovascular problems incident to, *May*, 374–7
hemorrhage in, *May*, 374
hypovolemic shock in, *May*, 374
surgery, advances in, *Feb.*, 34–8
Nodal rhythm, *May*, 334
Norepinephrine (Levophed). See also *Levarterenol.*
in supraventricular tachycardia, *May*, 329
in ventricular tachycardia, *May*, 340
Nuclear sex, *Feb.*, 175–6
Nucleus, steroid, of glycosides, *May*, 231
Nutrition. See also *Diet; Vitamins.*
undernutrition, relation to growth retardation, *Aug.*, 567–8

OBSTRUCTION, intestinal. See *Intestines, obstruction.*
Oliguria in glomerulonephritis, treatment, *Aug.*, 643
Omphalocele, surgical advances in, *Feb.*, 34–5
Operation. See *Surgery.*
Osteodystrophy, renal, relation to growth retardation, *Aug.*, 568–9
Ostium primum atrial septal defect, *Feb.*, 60, 122
treatment, *May*, 313
Ostium secundum atrial septal defect, *May*, 303–304
treatment, *May*, 312, 313
Ouabain, *May*, 238
Ovary. See also *Gonads.*
agenesis, *Feb.*, 48
tumors, *Feb.*, 52–4
Oxygen. See also *Respiration.*
saturation, postoperative, in cyanotic congenital heart disease, *May*, 290–91

Oxygen (*Continued*)
therapy, in heart failure, *May*, 265
in pneumonia complicating acyanotic congenital heart disease, *May*, 311
in respiratory distress syndrome, *May*, 387, 388
postoperative, in cyanotic congenital heart disease, *May*, 286

PACEMAKER, wandering, *May*, 321–2
Palate
cleft, *Feb.*, 183–200
roentgen evaluation, *Feb.*, **183–200**
soft, speech function, *Feb.*, 184
Pancreas
achylia, in cystic fibrosis, *Feb.*, 143
cystic fibrosis. See *Cystic fibrosis.*
enzymes, in cystic fibrosis, *Feb.*, 145
Parenteral fluids. See *Fluids, therapy, parenteral.*
Pathogens, urinary, *Aug.*, 518–21
incidence, *Aug.*, 521
susceptibility to chemotherapeutic agents, *Aug.*, 524–5
Pelvis. See also *Genitals.*
tumors, *Feb.*, 51–2
Penicillin
for prevention of recurrences of rheumatic fever, *May*, 223
in bacterial endocarditis, *May*, 487, 491
in enterococcal endocarditis, *May*, 490
in rheumatic fever, *May*, 217–18
in staphylococcal endocarditis, *May*, 490, 493
in streptococcal endocarditis, *May*, 488, 493
in streptococcal infections, *May*, 227; *Aug.*, 641
prophylaxis, after glomerulonephritis, *Aug.*, 645, 646
against bacterial endocarditis, *May*, 492
Pentolinium (Ansolysen) in hypertension, *May*, 454, 455
Pericardium, hemorrhage, postoperative, *May*, 286
Perinatal morbidity and mortality, pregnancy, and bacteriuria, *Aug.*, 748–9
Peritoneal compartment, absorptive potential, *Aug.*, 606
Peritoneal dialysis. See *Dialysis, peritoneal.*
Pharmacology. See also *Drugs.*
of digitalis, *May*, **229–45**
Phenergan. See *Promethazine hydrochloride.*
Phenobarbital
in cardiac arrhythmias, *May*, 358
in hypertensive glomerulonephritis, *Aug.*, 642
Phenomenon, Wenckebach's, *May*, 350–51
Phenylephrine hydrochloride (Neo-Synephrine)
in cardiac arrhythmias, *May*, 358
in supraventricular tachycardia, *May*, 329
in ventricular tachycardia, *May*, 340
Pheochromocytoma
hypertension due to, *May*, 447, 448
surgical treatment, results, *May*, 459
Phosphate in diabetic acidosis, *Feb.*, 10
Physical activity. See *Activity.*
Physical examination
in acyanotic congenital heart disease, *May*, 298–9
in cardiac failure in infancy, *May*, 249–52
in shock, *May*, 469
Physiology of speech, *Feb.*, 184–5
Plasma in shock in diarrhea, *Feb.*, 6
Plasmatic factors in renal disease, *Aug.*, 674
Platelets, reduction, in renal disease, *Aug.*, 673
Pneumatosis cystoides intestinalis in cystic fibrosis of pancreas, *Feb.*, 165
Pneumonia
complicating acyanotic congenital heart disease, treatment, *May*, 309–12
meconium aspiration, with acute cor pulmonale, *May*, 397–8
Poisoning, hypertension due to, *May*, 449
treatment, *May*, 458
Polyarteritis nodosa, renal manifestations, *Aug.*, 542–3
Postural drainage in cystic fibrosis of pancreas, *Feb.*, 145
Potassium
in cardiac arrhythmias, *May*, 360–61, 423
in diarrhea, *Feb.*, 7
in respiratory distress syndrome, *May*, 381
in ventricular extrasystoles, *May*, 338
in ventricular tachycardia, *May*, 340
Potassium acetate in digitalis toxicity, *May*, 237, 238
Potassium chloride
in dehydration, *Feb.*, 5
in digitalis toxicity, *May*, 237, 238, 263
in rheumatic fever, *May*, 222

Precocious puberty, *Feb.*, 54
Prednisone
in heart block, *May*, 348
in rheumatic fever, *May*, 221
Pregnancy, perinatal morbidity and mortality, and bacteriuria, *Aug.*, 748–9
Premature infants
dehydration in, *Feb.*, 10
fluid therapy in, *Feb.*, 10
Prematurity
and perinatal death in bacteriuric pregnant women, *Aug.*, 749
idiopathic respiratory distress syndrome of, *May*, 377–97
Pressure, positive, intermittent, in cystic fibrosis of pancreas, *Feb.*, 145
Probenecid (Benemid)
in staphylococcal endocarditis, *May*, 490, 493
in streptococcal endocarditis, *May*, 488, 493
Procaine amide (Pronestyl)
in cardiac arrhythmias, *May*, 360
in supraventricular tachycardia, *May*, 328
in ventricular extrasystoles, *May*, 337
in ventricular tachycardia, *May*, 340
Promethazine hydrochloride (Phenergan)
in cardiac arrhythmias, *May*, 358
Pronestyl. See *Procaine amide.*
Properdin, *Aug.*, 550
Prostigmin. See *Neostigmine.*
Protein
C-reactive, in rheumatic fever, *May*, 221
dietary, in renal acid-base disorders, *Aug.*, 627
Pseudoimmunologic process, *Aug.* 711
Pseudotruncus arteriosus, *Feb.*, 92, 130
Puberty, precocious, *Feb.*, 54
Pulmonary. See also *Lungs.*
arterial vessels. See *Arteries, pulmonary.*
arteriovenous fistula, *Feb.*, 100
blood vessels in congenital heart disease, *Feb.*, 128
hypertension, complicating ventricular septal defect, *Feb.*, 120
death in myocarditis due to, *May*, 414
primary, *Feb.*, 115; *May*, 307
secondary, *Feb.*, 133–4
to left-to-right shunt, *Feb.*, 124
with atrial septal defect, *Feb.*, 122
trunk, accessory coronary artery arising from, *Feb.*, 66
anomalous origin of left coronary artery from, *Feb.*, 66
valve, atresia, *Feb.*, 127, 130
Pulmonary (*Continued*)
valve, atresia, with intact ventricular septum and hypoplastic right ventricle, *Feb.*, 96
with intact ventricular septum and normal-sized right ventricle, *Feb.*, 96
with ventricular septal defect, *May*, 276–7
stenosis, *Feb.*, 115–16, 130–32, 135
complicating ventricular septal defect, *Feb.*, 120
complications, *Feb.*, 131, 132
origin of great vessels from right ventricle without, *Feb.*, 74
peripheral, *Feb.*, 115
single ventricle with, *Feb.*, 128
treatment, *May*, 306–307
vs. pulmonary atresia, *Feb.*, 127
with atrial septal defect, *Feb.*, 122
with intact ventricular septum and dilatation of pulmonary trunk, *Feb.*, 76
with intact ventricular septum and patent foramen ovale, *Feb.*, 96
with intact ventricular septum and right-to-left shunt at atrial level, *May*, 274–5
veins. See *Veins, pulmonary.*
Pulse. See also *Arrhythmias; Blood, pressure; Heart, beat.*
peripheral, in acyanotic congenital heart disease, *May*, 299
rate, normal, *May*, 316, 317
Purpura, thrombocytopenic, thrombotic, renal manifestations, *Aug.*, 543–4
Pyelonephritis, *Aug.*, **649–65, 731–58**
and diabetes mellitus, *Aug.*, 750
and hypertension, *Aug.*, 749–50
chronic, *Aug.*, 740, 741
clinical manifestations, *Aug.*, 739–42
diagnosis, *Aug.*, 742–50
frequency, *Aug.*, 732–4
hypertension due to, *May*, 439 ff.
incidence, *Aug.*, 649, 650
natural history, *Aug.*, 735–8
pathogenesis, *Aug.*, 734–5
pathology, *Aug.*, 734–5
prognosis, *Aug.*, 649–53, 752–4
relation of bacteriuria to, *Aug.*, 747
renal function in, *Aug.*, 656–63
symptoms, *Aug.*, 656–63
treatment, *Aug.*, 663–4, 750–52
Pyuria, *Aug.*, 745

QUINIDINE
in atrial fibrillation, *May*, 333

Quinidine (*Continued*)
in atrial flutter, *May*, 332
in cardiac arrhythmias, *May*, 357–60
in supraventricular tachycardia, *May*, 328
in ventricular extrasystoles, *May*, 337
in ventricular tachycardia, *May*, 340

REFLUX kidney infection, *Aug.*, 653–6
Renal. See also *Kidneys.*
artery. See *Arteries, renal.*
Research, medical, *Feb.*, 17–18
Reserpine (Serpasil)
in hypertension, *May*, 453, 454, 455
in hypertensive glomerulonephritis, *Aug.*, 642
Resistance and immunity to virus infections, mechanisms of, *Aug.*, **549–61**
Respiration
in heart failure, *May*, 250, 251
maintenance in shock, *May*, 470
mechanics, in cystic fibrosis of pancreas, *Feb.*, 147, 150
obstruction, postoperative, in cyanotic congenital heart disease, *May*, 285–6
rapid, in acyanotic congenital heart disease, *May*, 296–7
Respirator in respiratory distress syndrome, *May*, 391
weaning from, *May*, 393
Respiratory distress syndrome of prematurity, idiopathic, *May*, 377–97
Respiratory tract. See also *Lungs.*
in cystic fibrosis of pancreas, *Feb.*, 141
roentgen findings, *Feb.*, 146–52
treatment, *Feb.*, 144–5
infection, death in myocarditis due to, *May*, 414
obstruction in pneumonia complicating congenital heart disease, *May*, 312
Rest in heart failure, *May*, 265
Rheumatic carditis, acute, *May*, 216–17
Rheumatic fever, *May*, 213–28
and rheumatic heart disease, treatment and prevention, *May*, **213–28**
heart failure in, digitalis in, *May*, 222–3
Rheumatic heart disease and rheumatic fever, treatment and prevention, *May*, **213–28**
Rhythm, coronary sinus, *May*, 320
Rickets, vitamin D-refractory, relation to growth retardation, *Aug.*, 569
Roentgen evaluation in cleft palate, *Feb.*, **183–200**
Roentgen examination
in acyanotic congenital heart disease, *May*, 299, 300
in cardiac failure, *May*, 252, 253, 254

SALICYLATES in rheumatic fever, *May*, 218, 219, 220
Saline solution. See also *Sodium chloride.*
for airway obstruction in pneumonia complicating acyanotic congenital heart disease, *May*, 312
for gastric aspiration, *Feb.*, 5
for repair of stool losses, *Feb.*, 5
in dehydration, *Feb.*, 5
in hyponatremia, *Feb.*, 9
Salivary glands in cystic fibrosis of pancreas, *Feb.*, 143
Salt. See also *Sodium chloride.*
restriction in heart failure, *May*, 265
Sarcoma botryoides, *Feb.*, 51
Saventrine. See *Isoprenaline hydrochloride.*
Scleroderma, systemic, renal manifestations, *Aug.*, 542
Secobarbital (Seconal) in cardiac arrhythmias, *May*, 358
Seconal. See *Secobarbital.*
Sedation
in pneumonia complicating acyanotic congenital heart disease, *May*, 311
postoperative, in cyanotic congenital heart disease, *May*, 288
Sedatives in cardiac arrhythmias, *May*, 358
Self, alteration of, in immunologic disease, *Aug.*, 710
Senning operation for complete transposition of great vessels, *May*, 280
Sensitization, bacterial, in asthma, *Feb.*, 21–2
Septal defect, ventricular. See *Ventricular septal defect.*
Serpasil. See *Reserpine.*
Sex, nuclear, *Feb.*, 175–6
Shock
from cystic fibrosis, fluid therapy in, *Feb.*, 11–12
hypovolemic, in newborn, *May*, 374
in diarrhea, *Feb.*, 6
blood transfusion for, *Feb.*, 5, 6
medical, *May*, **465–81**
accompanying infection, *May*, 466–9
Shock syndrome in bacteremia, *May*, 468
Shohl's solution in acidosis, *Aug.*, 627
Shunt
blood. See *Blood, shunt.*
operations in tetralogy of Fallot, *May*, 271
Sinoatrial heart block, *May*, 341–2
Sinus
aortic. See *Aortic sinus.*
coronary, anomalous communication of coronary artery with, *Feb.*, 62
Sinus arrhythmia, *May*, 319–20

Sinus bradycardia, *May*, 318–19
Sinus node, rhythms originating from, *May*, 316–22
Sinus of Valsalva fistula, *Feb.*, 119
Sinus rhythm, coronary, *May*, 320
Sinus tachycardia, *May*, 317–18
Sinus venosus
  defects with atrial septal defect, *Feb.*, 123
  type of atrial septal defect, *Feb.*, 79
Skeleton. See *Bones.*
Skin diseases, fluid therapy in, *Feb.*, 12–13
Sodium
  in respiratory distress syndrome, *May*, 381
  loss in cystic fibrosis of pancreas, *Feb.*, 143
Sodium bicarbonate
  in acidosis, *Feb.*, 5
  in birth asphyxia, *May*, 371
  in cardiac arrest, *May*, 355
  in hyperkalemic glomerulonephritis, *Aug.*, 643
  in hypertonic dehydration, *Feb.*, 9
  in respiratory distress syndrome, *May*, 387
  postoperative use, *May*, 284
Sodium chloride. See also *Saline solution; Salt.*
  in cystic fibrosis of pancreas, *Feb.*, 144
Sodium lactate
  in cardiac arrhythmias, *May*, 360, 361
  in heart block, *May*, 348
  in hyperkalemic glomerulonephritis, *Aug.*, 643
Sodium nitroprusside in hypertension, *May*, 454
Sodium polystyrene sulfonate in hyperkalemic glomerulonephritis, *Aug.*, 643
Sodium Versenate. See *Bisodium ethylene diamine tetraacetic acid.*
Solutions. See also *Fluids.*
  for peritoneal dialysis. See under *Dialysis, peritoneal.*
  Shohl's, in acidosis, *Aug.*, 627
Sounds, cardiac. See *Heart, murmurs and sounds.*
Speech physiology, *Feb.*, 184–5
Spironolactone (Aldactone) in cardiac arrhythmias, *May*, 358
Staphylococci
  endocarditis, *May*, 489–90
  in urinary tract infections, *Aug.*, 520
Stenosis. See under organ or region affected.
Steroid nucleus of glycosides, *May*, 231
Steroid therapy
  in allergy, *Feb.*, 18–21
Steroid therapy (*Continued*)
  in eczema, *Feb.*, 20, 21
  in glomerulonephritis, *Aug.*, 644–5
  influence on adrenals, *Feb.*, 20
  side effects, *Feb.*, 19
Stokes-Adams syndrome, treatment, *May*, 348
Stomach. See also *Gastrointestinal tract.*
  aspiration, saline solution for, *Feb.*, 5
Stools. See *Feces.*
Streptococci
  infection, diagnosis, *Aug.*, 636
    treatment, *Aug.*, 641
  role in experimental renal disease, *Aug.*, 696–8
Streptococcus viridans, endocarditis, *May*, 487–9
Streptomycin
  in staphylococcal endocarditis, *May*, 490, 493
  in streptococcal endocarditis, *May*, 488, 493
  prophylaxis against bacterial endocarditis, *May*, 492
Subaortic stenosis
  distal to ventricular septal defect, *Feb.*, 70
  proximal to ventricular septal defect, *Feb.*, 70
Subpulmonary stenosis
  and mitral atresia with common ventricle, *Feb.*, 94
  and normal great vessels with tricuspid atresia, *Feb.*, 98
  and transposed great vessels, with tricuspid atresia, *Feb.*, 98
  and ventricular septal defect, with transposition of great vessels, *Feb.*, 90
  intact ventricular septum and closed ductus arteriosus, with transposition of great vessels, *Feb.*, 90
  with common ventricle, *Feb.*, 94
Sugar linkage of glycosides, *May*, 230
Sulfadiazine for prevention of recurrences of rheumatic fever, *May*, 224
Supraventricular tachycardia, *May*, 324–30
Surgery. See also *Drainage.*
  blood pressure response, *May*, 461
  for hypertension, *May*, 461
  gynecologic, *Feb.*, 45–54
    relation of congenital anomalies to, *Feb.*, 46–50
    relation of vaginal discharge to, *Feb.*, 50–52
  in cystic fibrosis of pancreas, *Feb.*, 145
  pediatric, advances in, *Feb.*, 33–44
    disappointments, *Feb.*, 42–3

Surgery (*Continued*)
pediatric, the future, *Feb.*, 43
Surgical patients, fluid therapy in, *Feb.*, 9–10
Sweat glands in cystic fibrosis of pancreas, *Feb.*, 143
treatment, *Feb.*, 146
Sweat test in cystic fibrosis of pancreas, *Feb.*, 144
Sweating, excessive, in acyanotic congenital heart disease, *May*, 297
Syndrome. See specific syndromes.

TACHYCARDIA
paroxysmal, atrial, with block, *May*, 330–31
repetitive, *May*, 330
sinus, *May*, 317–18
supraventricular, *May*, 324–30
ventricular, *May*, 338–40
Taussig-Bing complex or deformity, *Feb.*, 84, 133
Tear glands in cystic fibrosis of pancreas, *Feb.*, 143
Temperature, environmental, neutral, for birth asphyxia, *May*, 372
Tents, mist, in cystic fibrosis of pancreas, *Feb.*, 144–5
Teratoma, cystic, of ovary, *Feb.*, 52
Testes. See also *Gonads*.
undescended, *Feb.*, 41
Testicular feminization, *Feb.*, 49
Tests
for bacteriuria, *Aug.*, 744
Griess nitrite, *Aug.*, 523
sweat, in cystic fibrosis of pancreas, *Feb.*, 144
triphenyl tetrazolium chloride, *Aug.*, 524
urinary catalase, *Aug.*, 523, 524
Tetany, postacidotic, calcium gluconate in, *Feb.*, 5
Tetracycline in staphylococcal endocarditis, *May*, 490, 493
Tetralogy of Fallot, *Feb.*, 92, 134; *May*, 270–74
with pulmonic stenosis, *Feb.*, 131
THAM in acidosis due to birth asphyxia, *May*, 371, 372
Theophylline in cardiac arrhythmias, *May*, 359
Therapy
cardiovascular, symposium on, *May*, **211–495**
fluid. See *Fluids, therapy*.
Thiomerin. See *Mercaptomerin*.
Thorazine. See *Chlorpromazine*.
Thrombocytopenia
hemolytic anemia and renal disease, *Aug.*, **577–91**
nephropathy and hemolysis, syndrome of, *Aug.*, 675–81
Thromboembolism, *Aug.*, 533, 534
Thromboplastic function in renal disease, *Aug.*, 673
Thrombosis. See also *Emboli*.
of glomerular capillaries and arterioles, *Aug.*, 540–41
of renal artery, *Aug.*, 537–40
diagnosis, *Aug.*, 539
treatment, *Aug.*, 539
of renal veins, *Aug.*, 534–7
diagnosis, *Aug.*, 536
treatment, *Aug.*, 537
renal vessel, *Aug.*, 533–41
Thyroid, hyperthyroidism, hypertension due to, *May*, 448
Tranquilizers in cardiac arrhythmias, *May*, 358
Transfusion. See under *Blood*.
Translocation, chromosomal, *Feb.*, 174, 180
Transposition of great vessels. See *Blood vessels, great transposition of*.
Trauma to external female genitalia, *Feb.*, 54
Tricuspid valve
and right ventricle, hypoplasia of, *Feb.*, 98
atresia, *Feb.*, 127, 134; *May*, 281–2
with common ventricle and transposed great vessels, *Feb.*, 86
with normal great vessels, *Feb.*, 86
with subpulmonary stenosis and normal great vessels, *Feb.*, 98
with subpulmonary stenosis and transposed great vessels, *Feb.*, 98
Ebstein's malformation, *Feb.*, 98
Trigeminy, *May*, 334
Trimethaphan (Arfonad) in hypertension, *May*, 454
Triphenyl tetrazolium chloride test, *Aug.*, 524
Trisomic syndromes, *Feb.*, 176–7
Trisomy. See under *Chromosomes*.
Truncus arteriosus, *Feb.*, 118–19, 127–8, 133
persistent, *Feb.*, 84, 92
TTC. See *Triphenyl tetrazolium chloride*.
Tubes, visceral, replacement of esophagus, *Feb.*, 41
Tumors
ovarian. See *Ovary, tumors*.
pelvic, *Feb.*, 51–2
Wilms's. See under *Kidneys, tumors*.
Turner's syndrome. See *Gonads, dysgenesis*.

UNDERNUTRITION, relation to growth retardation, *Aug.*, 567–8
Uremia. See also *Kidneys; Nephritis;* etc.
relation to growth retardation, *Aug.*, 567
Uremic hemolytic syndrome. See *Hemolytic-uremic syndrome.*
Urinalysis
in pyelonephritis, *Aug.*, 742–6
qualitative, *Aug.*, 744–6
quantitative, *Aug.*, 742–3
microscopic, *Aug.*, 522
Urinary catalase test, *Aug.*, 523, 524
Urinary pathogens. See *Pathogens, urinary.*
Urinary tract. See also *Genitals.*
anomalies, pyelonephritis due to, *Aug.*, 737, 738
bacteriology, quantitative aspects, *Aug.*, 522–4
catheter in, dangers of, *Feb.*, 43
infections, *Aug.*, 731
bacteremia with, *Aug.*, 525
bacteriologic findings, interpretation of, *Aug.*, 525–8
bacteriology and immune response in, *Aug.*, **517–31**
effects of endotoxin, *Aug.*, 529
immune response, *Aug.*, 528–9
prognosis, *Aug.*, 753
Urine. See also *Diuresis and diuretics.*
acidification, *Aug.*, 612
bacteria. See *Bacteriuria.*
collection, *Aug.*, 744, 745
contamination, vs. bacteriuria, *Aug.*, 743
cultural study, *Aug.*, 522, 523
enzymatic reactions, *Aug.*, 523, 524
examination. See *Urinalysis.*
Uterus, tumors, *Feb.*, 51

VAGINA
absence, congenital, *Feb.*, 47
discharge, relation to surgery, *Feb.*, 50–52
foreign bodies in, *Feb.*, 50–51
tumors, *Feb.*, 51
Valsalva, sinus of, fistula, *Feb.*, 119
Vascular. See *Blood vessels.*
Vasopressors in cardiac arrhythmias, *May*, 358
Veins. See also *Arteries; Blood vessels; Cardiovascular system; Pulse;* etc.
pulmonary, anomalous connection to right atrium or a systemic vein, *Feb.*, 60
anomalous pulmonary venous connection to, *Feb.*, 60

Veins (*Continued*)
pulmonary, drainage, anomalous, partial, with atrial septal defect, *Feb.*, 123
total, *Feb.*, 129–30; *May*, 277–8
stenosis, treatment, *May*, 307
total anomalous connection, *Feb.*, 84
venous return, partial anomaly of, *May*, 303–304
renal, thrombosis of, *Aug.*, 534–7
systemic, anomalous pulmonary venous connection to, *Feb.*, 60
connection with left atrium, *Feb.*, 100
total anomalous connection, *May*, 278
Ventricles
common, and transposed great vessels, with mitral atresia, *Feb.*, 86
with tricuspid atresia, *Feb.*, 86
with subpulmonary stenosis, *Feb.*, 94
with subpulmonary stenosis and mitral atresia, *Feb.*, 94
with transposition of great vessels and patent atrioventricular valves, *Feb.*, 86
left, communication with right atrium *Feb.*, 62
endocardial fibroelastosis of, treatment, *May*, 308
failure of, due to shunts, *May*, 266
origin of great vessels from, without pulmonary stenosis, *Feb.*, 74
rhythms arising in, *May*, 334–41
right, *Feb.*, 57
and tricuspid valve, hypoplasia of, *Feb.*, 98
communication of coronary artery with, *Feb.*, 64
double outlet, *Feb.*, 74
hypoplastic, and intact ventricular septum, pulmonary atresia with, *Feb.*, 96
large, with pulmonary atresia, *Feb.*, 130
normal-sized, and intact ventricular septum, with pulmonary atresia, *Feb.*, 96
origin of great vessels from, with pulmonary stenosis, *Feb.*, 92
without pulmonary stenosis, *Feb.*, 84
rupture of aortic sinus aneurysm into, *Feb.*, 64
single, *Feb.*, 133
complicating ventricular septal defect, *Feb.*, 120
with pulmonic stenosis, *Feb.*, 128, 131

Ventricular extrasystoles due to digitalis, *May*, 236
Ventricular fibrillation, *May*, 340–41
Ventricular hypertrophy, *Feb.*, 108
combined, *Feb.*, 108
with left-to-right shunt, *Feb.*, 123–4
with no shunt, *Feb.*, 116–17
with right-to-left shunt, *Feb.*, 134
left, *Feb.*, 108
with left-to-right shunt, *Feb.*, 117–21
with no shunt, *Feb.*, 110–13
with right-to-left shunt, *Feb.*, 125–8
with shunts arising from aorta, *Feb.*, 117–19
right, *Feb.*, 108
with left-to-right shunt, *Feb.*, 121–3
with no shunt, *Feb.*, 114–17
with right-to-left shunt, *Feb.*, 128–9
Ventricular premature beats, *May*, 334–8
Ventricular septum
defect, *Feb.*, 119–21, 124, 135
and interatrial communication with transposition of great vessels, *Feb.*, 88
and subpulmonary stenosis, with transposition of great vessels, *Feb.*, 90
complicated, *Feb.*, 120–21
inferior to crista supraventricularis, *Feb.*, 74
large, *Feb.*, 70
and corrected transposition of great vessels, *Feb.*, 72
and corrected transposition of great vessels with pulmonary vascular disease, *Feb.*, 80
and patent ductus arteriosus, interruption of aortic arch proximal to, *Feb.*, 82
with occlusive pulmonary vascular disease, *Feb.*, 80
with pulmonic stenosis, *Feb.*, 131
mitral insufficiency, and corrected transposition of great vessels, *Feb.*, 72
small, *Feb.*, 64
subaortic stenosis distal to, *Feb.*, 70
subaortic stenosis proximal to, *Feb.*, 70
treatment, *May*, 313–14
vs. pulmonic stenosis, *Feb.*, 116
with atrial septal defect, *Feb.*, 122–3
with pulmonary atresia, *Feb.*, 130; *May*, 276–7
with pulmonic stenosis, *Feb.*, 131
intact, and closed ductus arteriosus, transposition of great vessels with, *Feb.*, 90
Ventricular septum (*Continued*)
intact, and dilatation of pulmonary trunk, pulmonary valvular stenosis with, *Feb.*, 76
and hypoplastic right ventricle, pulmonary atresia with, *Feb.*, 96
and normal-sized right ventricle, with pulmonary atresia, *Feb.*, 96
and patent foramen ovale, with pulmonary stenosis, *Feb.*, 96
and right-to-left shunt at atrial level, with pulmonic stenosis, *May*, 274–5
subpulmonary stenosis and closed ductus arteriosus, with transposition of great vessels, *Feb.*, 90
Ventricular shunt, left-to-right, *May*, 304–305
Ventricular tachycardia, *May*, 338–40
Viruses
infections, classification of, *Aug.*, 555
host defenses to, *Aug.*, 550
immunity in, proposed mechanisms, *Aug.*, 555–8
mechanisms of immunity and resistance to, *Aug.*, **549–61**
primary, *Aug.*, 556
secondary, *Aug.*, 556
renal disease due to, *Aug.*, 558–9
Visceral tubes, replacement of esophagus, *Feb.*, 41
Vitamin D-refractory rickets, relation to growth retardation, *Aug.*, 569
Vitamins
deficiency, in cystic fibrosis of pancreas, *Feb.*, 143
in cystic fibrosis of pancreas, *Feb.*, 145–6
Vomiting
due to digitalis, *May*, 235
fluid therapy in, *Feb.*, 11
Vulva, tumors, *Feb.*, 51

WATER. See also *Fluids.*
intoxication, fluid therapy in, *Feb.*, 9
Wenckebach's phenomenon, *May*, 350–51
Wilms's tumor. See under *Kidneys, tumors.*
Window, aorticopulmonary, *Feb.*, 118
Wolff-Parkinson-White syndrome, *May*, 351–2
death in myocarditis due to, *May*, 419
Wyamine. See *Mephentermine.*

XYLOCAINE. See *Lidocaine.*